Similar articles

• Pharmacokinetics of midazolam in relation to polymorphic sparteine oxidation.

  Klotz U, Mikus G, Zekorn C, Eichelbaum M. Klotz U, et al. Br J Clin Pharmacol. 1986 Nov;22(5):618-20. doi: 10.1111/j.1365-2125.1986.tb02946.x. Br J Clin Pharmacol. 1986. PMID: 3790411 Free PMC article. No abstract available.
• Influence of the defective metabolism of sparteine on its pharmacokinetics.

  Eichelbaum M, Spannbrucker N, Dengler HJ. Eichelbaum M, et al. Eur J Clin Pharmacol. 1979 Sep;16(3):189-94. doi: 10.1007/BF00562060. Eur J Clin Pharmacol. 1979. PMID: 499319
• Proceedings: N-oxidation of sparteine in man and its interindividual differences.

  Eichelbaum M, Spannbrucker N, Dengler HJ. Eichelbaum M, et al. Naunyn Schmiedebergs Arch Pharmacol. 1975;287 Suppl:R94. Naunyn Schmiedebergs Arch Pharmacol. 1975. PMID: 1143521 No abstract available.
• Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation.

  Backman JT, Mäenpää J, Belle DJ, Wrighton SA, Kivistö KT, Neuvonen PJ. Backman JT, et al. Clin Pharmacol Ther. 2000 Apr;67(4):382-90. doi: 10.1067/mcp.2000.105756. Clin Pharmacol Ther. 2000. PMID: 10801247 Clinical Trial.
• Pharmacokinetics and the sedative effect of midazolam.

  Kanto J, Allonen H. Kanto J, et al. Int J Clin Pharmacol Ther Toxicol. 1983 Sep;21(9):460-3. Int J Clin Pharmacol Ther Toxicol. 1983. PMID: 6138314 Review.